Access to the information and documents on this part of the website is restricted for regulatory reasons. You are requested to review the following information and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate.
Please enter your country of residence:
I am currently physically present in:
Continue
IMPORTANT INFORMATION
Access to the information and documents on this portion of the website is restricted for regulatory reasons. You are requested to review the following information and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate.
The information contained in this section of the website of Infant Bacterial Therapeutics AB (publ) (the “Company”) is (a) only intended for, and may only be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident and physically present outside the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the “United States”), Australia, Canada, New Zealand, Hong Kong, Japan, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus and resident and physically present in a jurisdiction where to do so will not constitute a violation of the local securities laws or regulations of such jurisdiction, and (b) does not constitute an offer to sell or the solicitation of an offer to buy or acquire any securities of the Company in the United States, Australia, Canada, New Zealand, Hong Kong, Japan, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or any other jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.
The securities of the Company referred to in this section of the website (the “Securities”) have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or with any securities regulatory authority of any state of the United States for offer or sale as part of their distribution and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. The Securities have not been and will not be registered under the applicable securities laws of Australia, Canada, New Zealand, Hong Kong, Japan, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or any other jurisdiction in which it would be unlawful or would require registration or other measures, and therefore may not be offered or sold to or for the account or benefit of any person having a registered address in, or located or resident in, Australia, Canada, New Zealand, Hong Kong, Japan, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or any other jurisdiction in which it would be unlawful or would require registration or other measures.
In the United Kingdom, the information contained in this section of the Company’s website is only being distributed to and is only directed at “qualified investors” within the meaning of Article 2(e) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (together with any related implementing and delegated regulations, the “Prospectus Regulation”), as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 who are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i) and (ii) above together being referred to as “relevant persons”). The Securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on the information contained in this section of the Company’s website.
In Australia, the information contained in this section of the Company’s website is only being provided to you on the basis that you are a person to whom an offer of the Securities may be made without a prospectus or other form of disclosure document, in accordance with section 708 of the Corporations Act 2001 (Cth) (the “Corporations Act”). In particular: (1) no offers or applications will be made or invited for the issue, sale, or purchase of any Securities (including an offer or invitation which is received by a person in Australia); and (2) documents on this website or any other offering material or advertisement relating to the offering of Securities will not be distributed or published in Australia, unless in either case (1) or (2), (i) the minimum aggregate consideration payable by each offeree or invitee is at least A$500,000 (or the equivalent in another currency, in either case disregarding moneys lent by the offeror or its associates) or the offer otherwise does not require disclosure to investors in accordance with Part 6D.2 or Chapter 7 of the Corporations Act, (ii) the offer or invitation of Securities or distribution of documents on this website are not to a “retail client” for the purposes of Section 761G of the Corporations Act and (iii) such action complies with all applicable laws, regulations and directives in relation to the offer or invitation of Securities or distribution of documents on this website and does not require any document to be lodged with, or registered by, the Australian Securities & Investments Commission (“ASIC”) or any regulatory authority in Australia. Accordingly, documents on this website are not and is not intended to be a prospectus or other form of disclosure document for the purposes of the Corporations Act that is required to be lodged with ASIC. Therefore, documents on this website are not required to, and does not, contain all the information that would be contained in a prospectus or other form of disclosure document under the Corporations Act. Securities issued pursuant to any offer may not be offered for sale (or transferred, assigned or otherwise alienated) to any person located in, or a resident of, Australia for at least 12 months after their issue, except in circumstances where the person is a person to whom a disclosure document or product disclosure statement is not required to be given under Chapter 6D or Chapter 7 of the Corporations Act.
In any EEA Member State, other than Sweden, where the Prospectus Regulation is applicable, the information contained in this section of the Company’s website are only addressed to and are only directed at qualified investors within the meaning of the Prospectus Regulation.
Access to the information contained on this portion of the website may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such information and documents. All persons who wish to have access to the documents contained in this section of the Company’s website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this section of the website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been or will be obtained. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
I therefore certify that:
1. I am resident and physically present in a country outside the United States, Australia, Canada, New Zealand, Hong Kong, Japan, Switzerland, Singapore, South Africa, South Korea, Russia and Belarus;
2. I am authorized to access the information and documents contained on this portion of the website without being subject to any legal restriction and without any further action required by the Company; and
3. I will not transmit or otherwise send any information contained in this website to publications with a general circulation in the United States
I confirm I cannot confirm
I have read, understand and agree to comply with all of the restrictions set forth above.
I confirm I cannot confirm
Share Issue 2023
PR 20230704 – IBT announces outcome of its rights issue
IBT Prospectus (Swedish)
Application form – Subscription for shares with subscription rights
Application form – Subscription for shares with subsidiary preferential right or without subscription rights
PR 20230613 Prospectus
IBT resolves on a rights issue
The board of directors’ report in accordance with Chapter 13 Section 6 of the Swedish Companies Act
Archive (2017-2018)
Infant Bacterial Therapeutics announces capital raise of approximately SEK 545 million in total
The board of directors’ report in accordance with Chapter 13 Section 6 of the Swedish Companies Act
The board of directors’ rights issue resolution
The board of directors’ resolution on a directed share issue
Notice of extraordinary general meeting in Infant Bacterial Therapeutics
Archive (2016)
IBT publishes the Prospectus
IBT Press Realease 20160427 (English) – Prospectus
Application form, with preferential rights
Application form, without preferential rights
IBT announces fully underwritten SEK 100 million rights issue
IBT Press Release 20160427 (English) – IBT announces fully underwritten SEK 100 million rights issue
The board of directors’ of Infant Bacterial Therapeutics AB (publ) resolution to issue new shares
The auditor’s statement in accordance with Chapter 13 Section 6 of the Swedish Companies Act
DISCLAIMER – IMPORTANT
Due to applicable legal restrictions, the information contained in this section of the website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the United States of America, Australia, Canada, New Zealand, Hong Kong, Japan, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or any other jurisdiction in which such release, publication or distribution would be unlawful. We apologize for any inconvenience this may cause. Click here to return to the homepage.